Literature DB >> 28126245

Double-blind placebo-controlled randomized clinical trial of verapamil for chronic rhinosinusitis with nasal polyps.

Marcel M Miyake1, Angela Nocera2, Patricia Levesque2, Rong Guo3, Christine A Finn4, Jeremy Goldfarb5, Stacey Gray2, Eric Holbrook2, Nicolas Busaba2, Jose Eduardo L Dolci6, Benjamin S Bleier7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28126245     DOI： 10.1016/j.jaci.2016.11.014

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  6 in total

1.  Cystatin SN is a potent upstream initiator of epithelial-derived type 2 inflammation in chronic rhinosinusitis.

Authors:  Angela L Nocera; Sarina K Mueller; Alan D Workman; Dawei Wu; Kristen McDonnell; Peter M Sadow; Mansoor M Amiji; Benjamin S Bleier
Journal:  J Allergy Clin Immunol       Date:  2022-05-31       Impact factor: 14.290

Review 2.  Mechanisms and pathogenesis of chronic rhinosinusitis.

Authors:  Atsushi Kato; Robert P Schleimer; Benjamin S Bleier
Journal:  J Allergy Clin Immunol       Date:  2022-03-01       Impact factor: 14.290

Review 3.  Biomarkers in Chronic Rhinosinusitis with Nasal Polyps.

Authors:  Alan D Workman; Michael A Kohanski; Noam A Cohen
Journal:  Immunol Allergy Clin North Am       Date:  2018-09-21       Impact factor: 3.479

Review 4.  P-glycoprotein and chronic rhinosinusitis.

Authors:  Marcel M Miyake; Angela Nocera; Michelle M Miyake
Journal:  World J Otorhinolaryngol Head Neck Surg       Date:  2018-08-24

Review 5.  Exosomes and chronic rhinosinusitis.

Authors:  Sarina K Mueller
Journal:  World J Otorhinolaryngol Head Neck Surg       Date:  2018-11-01

Review 6.  Roles of Exosomes in Chronic Rhinosinusitis: A Systematic Review.

Authors:  Karolina Dżaman; Katarzyna Czerwaty
Journal:  Int J Mol Sci       Date:  2022-09-25       Impact factor: 6.208
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.